Emergent BioSolutions (EBS) Common Equity (2010 - 2026)

Emergent BioSolutions' Common Equity history runs 17 years deep, the most recent figure standing at $523.1 million for Q1 2026.

• On a quarterly basis, Common Equity fell 5.36% year-over-year to $523.1 million in Q1 2026; TTM through Mar 2026 was $523.1 million, a 5.36% decrease from a year earlier, with the FY2025 full-year figure at $522.6 million, up 8.24% from the prior year.
• Common Equity was little changed at $523.1 million in Q1 2026 per EBS's latest filing, from $522.6 million in the prior quarter.
• Across five years, Common Equity topped out at $1.6 billion in Q1 2022 and bottomed at $386.3 million in Q2 2024.
• The 5-year median for Common Equity is $649.3 million (2023), against an average of $833.1 million.
• Across the five-year window, Common Equity sank 59.66% in 2024 and jumped 38.8% in 2025, its largest moves.
• Year by year, Common Equity stood at $1.4 billion in 2022, then sank by 53.21% to $649.3 million in 2023, then slipped by 25.64% to $482.8 million in 2024, then rose by 8.24% to $522.6 million in 2025, then gained by 0.1% to $523.1 million in 2026.
• Per Business Quant, the three latest EBS Common Equity figures stand at $523.1 million (Q1 2026), $522.6 million (Q4 2025), and $582.5 million (Q3 2025).